As of December 31, 2024, ARS Pharma had cash, cash equivalents, and short-term investments of $314.0 million, with 97,954,172 shares of common stock outstanding. The company reiterates its guidance that its financial position is expected to support its operating plans for at least the next three years.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRY:
- ARS Pharmaceuticals reports FY24 EPS 8c, consensus (56c)
- SPRY Upcoming Earnings Report: What to Expect?
- Tesla upgraded, Coinbase initiated: Wall Street’s top analyst calls
- ARS Pharmaceuticals initiated with an Outperform at Scotiabank
- ARS Pharmaceuticals: Strategic Developments and Market Opportunities Drive Buy Rating for Neffy
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue